<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01302028</url>
  </required_header>
  <id_info>
    <org_study_id>1941-CL-0064</org_study_id>
    <secondary_id>2009-011320-61</secondary_id>
    <nct_id>NCT01302028</nct_id>
  </id_info>
  <brief_title>Renal Impairment Study With ASP1941</brief_title>
  <official_title>An Open-label, Parallel Group Study to Assess the Effect of Different Grades of Renal Impairment in Patients With Type 2 Diabetes Mellitus on the Pharmacokinetics, Pharmacodynamics and Safety &amp; Tolerability of ASP1941 Relative to Type 2 Diabetes Mellitus With Normal Renal Function and Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to investigate if the pharmacokinetics of ASP1941 is different in Type 2 Diabetes
      Mellitus (T2DM) patients with different grades of renal failure compared with T2DM patients
      with normal renal function and healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 22, 2010</start_date>
  <completion_date type="Actual">June 26, 2010</completion_date>
  <primary_completion_date type="Actual">June 26, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of grade of renal impairment on the pharmacokinetics of ASP1941</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of grade of renal impairment on the pharmacodynamics of ASP1941</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety through evaluation of adverse events, physical examination, vital sins, lab-tests and 12-lead ECG</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers with normal renal function</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM patient with normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM patient with mild renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM patient with moderate renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM patient with severe renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1941</intervention_name>
    <description>Oral</description>
    <arm_group_label>T2DM patient with mild renal impairment</arm_group_label>
    <arm_group_label>T2DM patient with severe renal impairment</arm_group_label>
    <arm_group_label>T2DM patient with normal renal function</arm_group_label>
    <arm_group_label>T2DM patient with moderate renal impairment</arm_group_label>
    <arm_group_label>Healthy volunteers with normal renal function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with stable type 2 diabetes mellitus or healthy subject

          -  Subject must have pre-dose estimated Glomerular filtration rate (GFR) values
             (Modification of diet in renal disease (MDRD) method) at screening of:

               -  &gt;90 (normal renal function)

               -  60-90 (mild renal impairment)

               -  30-60 (moderate renal impairment)

               -  15-30 (severe renal impairment)

          -  BMI between 25.0-40.0 kg/m2, inclusive

          -  Fasted plasma glucose (FPG) &lt;11.5 mmol/l (type 2 DM patients) or &gt;5.6 mmol/l (Healthy
             volunteers)

        Exclusion Criteria:

          -  Patients with Type 1 diabetes

          -  Pulse &lt;40 or &gt;90; SBP &gt;160 mmHg; DBP &gt; 100 mmHg

          -  T2DM patients who are not on a stable regimen for their current medication (1 month or
             5 half lives, whichever is longer) to control their disease

          -  Healthy Volunteers: Any of the liver function tests above the upper limit of normal

          -  T2DM: The liver function tests should be within the following ranges:

               -  AST/ALT: &lt;2 x ULN

               -  Bilirubin: &lt;1.5 x ULN

               -  Alk Phos: &lt; 1.5 x ULN

          -  Patients with renal impairment who have a history of a clinically significant illness
             (other than renal diseases and T2DM and associated clinical symptoms), medical
             condition, or laboratory abnormality within 3 months prior to screening

          -  Patients with renal impairment who have not been on a stable dose of concomitant
             medications for at least 2 weeks for at least 2 weeks (or 5 halflives, whichever is
             longer) and/or for whom dose changes are likely to occur during the study

          -  Patients with T2DM treated with a diet only

          -  T2DM patients with recent evidence (e.g within the last 6 months) of severe
             hypoglycemia, for example plasma glucose &lt; 3mmol/l (&lt;55 mg/dl), help from others to
             resolve the hypo or requiring hospitalization

          -  T2DM patients with a Hemoglobin value &lt; 9 g/dl (5.6 mmol/l)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <zip>16900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Balatonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <zip>83305</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Slovakia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/study.aspx?ID=6</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2011</study_first_submitted>
  <study_first_submitted_qc>February 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Impairment</keyword>
  <keyword>ASP1941</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

